Table 3.
Antimicrobial susceptibility patterns of E. coli isolates associated with CA- and HCA-BSIs.
| Antimicrobial susceptibility patterns of E. coli isolates | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | All (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Amoxicillin S | 81 | 137 | 140 | 147 | 175 | 182 | 175 | 158 | 163 | 201 | 1559 (46.8) |
| In CA-BSIs | 55 | 97 | 97 | 98 | 128 | 129 | 133 | 115 | 112 | 135 | 1099 (49.7) |
| In HCA-BSIs | 26 | 40 | 43 | 49 | 47 | 53 | 42 | 43 | 51 | 66 | 460 (40.9) |
| Amoxicillin R cefotaxime S | 77 | 129 | 175 | 153 | 149 | 146 | 153 | 157 | 185 | 198 | 1522 (45.6) |
| In CA-BSIs | 49 | 84 | 114 | 100 | 98 | 89 | 92 | 98 | 115 | 128 | 967 (43.8) |
| In HCA-BSIs | 28 | 45 | 61 | 53 | 51 | 57 | 61 | 59 | 70 | 70 | 555 (49.3) |
| Amoxicillin R cefotaxime R ESBL+ | 1 | 5 | 7 | 11 | 8 | 14 | 14 | 20 | 26 | 32 | 138 (4.1) |
| In CA-BSIs | 3 | 2 | 6 | 3 | 5 | 6 | 8 | 16 | 12 | 61 (2.8) | |
| In HCA-BSIs | 1 | 2 | 5 | 5 | 5 | 9 | 8 | 12 | 10 | 20 | 77 (6.8) |
| Amoxicillin R cefotaxime R (no ESBL) | 3 | 2 | 2 | 1 | 5 | 5 | 4 | 13 | 9 | 5 | 49 (1.5) |
| In CA-BSIs | 1 | 1 | 3 | 3 | 3 | 9 | 6 | 4 | 30 (1.4) | ||
| In HCA-BSIs | 2 | 2 | 2 | 2 | 2 | 1 | 4 | 3 | 1 | 19 (1.7) | |
| Not known | 4 | 5 | 9 | 11 | 20 | 5 | 1 | 3 | 1 | 7 | 66 (2.0) |
| All (CA-BSIs/HCA-BSIs) | 166 (108/58) | 278 (187/91) | 333 (221/112) | 323 (213/110) | 357 (249/108) | 352 (231/121) | 347 (235/112) | 351 (231/120) | 384 (250/134) | 443 (284/159) | 3334 (2209/1125) |